Cargando…
Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage
OBJECTIVES: The aim of this dual‐center randomized controlled trial was to determine the optimal duration of antimicrobial prophylaxis in patients treated with pancreaticoduodenectomy (PD) who underwent preoperative biliary drainage (PBD) but were without cholangitis. BACKGROUND: Some reports showed...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236101/ https://www.ncbi.nlm.nih.gov/pubmed/30460348 http://dx.doi.org/10.1002/ags3.12209 |
_version_ | 1783370972759326720 |
---|---|
author | Yamamoto, Tomohisa Satoi, Sohei Fujii, Tsutomu Yamada, Suguru Yanagimoto, Hiroaki Yamaki, So Takami, Hideki Hirooka, Satoshi Kosaka, Hisashi Kotsuka, Masaya Miyara, Takayuki Kodera, Yasuhiro |
author_facet | Yamamoto, Tomohisa Satoi, Sohei Fujii, Tsutomu Yamada, Suguru Yanagimoto, Hiroaki Yamaki, So Takami, Hideki Hirooka, Satoshi Kosaka, Hisashi Kotsuka, Masaya Miyara, Takayuki Kodera, Yasuhiro |
author_sort | Yamamoto, Tomohisa |
collection | PubMed |
description | OBJECTIVES: The aim of this dual‐center randomized controlled trial was to determine the optimal duration of antimicrobial prophylaxis in patients treated with pancreaticoduodenectomy (PD) who underwent preoperative biliary drainage (PBD) but were without cholangitis. BACKGROUND: Some reports showed that PBD in patients undergoing pancreatectomy increased the rate of perioperative complications. However, no clinical trial has evaluated the optimal duration of antimicrobial prophylaxis with a focus on patients who underwent PD following PBD. METHODS: A total of 82 patients who underwent PD between March 2012 and December 2016 were randomly assigned to either a 1‐day group (n = 40), in which cefozopran (CZOP) as antimicrobial prophylaxis was given only on the day of surgery, or a 5‐day group (n = 42), in which CZOP was given for 5 consecutive days beginning on the day of surgery. We evaluated the incidence of infectious and other complications after PD. RESULTS: Outcomes were significantly better in the 1‐day group compared with the 5‐day group (P < 0.05) in terms of the incidence of overall infectious complications (15% vs 36%, respectively), intra‐abdominal abscess (3% vs 21%, respectively), clinically relevant postoperative pancreatic fistula (8% vs 24%, respectively), and Clavien‐Dindo grade III‐V complications (10% vs 31%, respectively). Duration of postoperative hospital stay was significantly shorter in the 1‐day group (10 days vs 15 days, P = 0.018). Anaerobic bacteria and methicillin‐resistant cocci were isolated from the drainage fluid only among patients in the 5‐day group. CONCLUSION: Single‐day prophylactic use of CZOP is appropriate for patients who undergo PD following PBD without preoperative cholangitis. |
format | Online Article Text |
id | pubmed-6236101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-62361012018-11-20 Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage Yamamoto, Tomohisa Satoi, Sohei Fujii, Tsutomu Yamada, Suguru Yanagimoto, Hiroaki Yamaki, So Takami, Hideki Hirooka, Satoshi Kosaka, Hisashi Kotsuka, Masaya Miyara, Takayuki Kodera, Yasuhiro Ann Gastroenterol Surg Original Articles OBJECTIVES: The aim of this dual‐center randomized controlled trial was to determine the optimal duration of antimicrobial prophylaxis in patients treated with pancreaticoduodenectomy (PD) who underwent preoperative biliary drainage (PBD) but were without cholangitis. BACKGROUND: Some reports showed that PBD in patients undergoing pancreatectomy increased the rate of perioperative complications. However, no clinical trial has evaluated the optimal duration of antimicrobial prophylaxis with a focus on patients who underwent PD following PBD. METHODS: A total of 82 patients who underwent PD between March 2012 and December 2016 were randomly assigned to either a 1‐day group (n = 40), in which cefozopran (CZOP) as antimicrobial prophylaxis was given only on the day of surgery, or a 5‐day group (n = 42), in which CZOP was given for 5 consecutive days beginning on the day of surgery. We evaluated the incidence of infectious and other complications after PD. RESULTS: Outcomes were significantly better in the 1‐day group compared with the 5‐day group (P < 0.05) in terms of the incidence of overall infectious complications (15% vs 36%, respectively), intra‐abdominal abscess (3% vs 21%, respectively), clinically relevant postoperative pancreatic fistula (8% vs 24%, respectively), and Clavien‐Dindo grade III‐V complications (10% vs 31%, respectively). Duration of postoperative hospital stay was significantly shorter in the 1‐day group (10 days vs 15 days, P = 0.018). Anaerobic bacteria and methicillin‐resistant cocci were isolated from the drainage fluid only among patients in the 5‐day group. CONCLUSION: Single‐day prophylactic use of CZOP is appropriate for patients who undergo PD following PBD without preoperative cholangitis. John Wiley and Sons Inc. 2018-09-17 /pmc/articles/PMC6236101/ /pubmed/30460348 http://dx.doi.org/10.1002/ags3.12209 Text en © 2018 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Yamamoto, Tomohisa Satoi, Sohei Fujii, Tsutomu Yamada, Suguru Yanagimoto, Hiroaki Yamaki, So Takami, Hideki Hirooka, Satoshi Kosaka, Hisashi Kotsuka, Masaya Miyara, Takayuki Kodera, Yasuhiro Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage |
title | Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage |
title_full | Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage |
title_fullStr | Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage |
title_full_unstemmed | Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage |
title_short | Dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage |
title_sort | dual‐center randomized clinical trial exploring the optimal duration of antimicrobial prophylaxis in patients undergoing pancreaticoduodenectomy following biliary drainage |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236101/ https://www.ncbi.nlm.nih.gov/pubmed/30460348 http://dx.doi.org/10.1002/ags3.12209 |
work_keys_str_mv | AT yamamototomohisa dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT satoisohei dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT fujiitsutomu dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT yamadasuguru dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT yanagimotohiroaki dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT yamakiso dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT takamihideki dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT hirookasatoshi dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT kosakahisashi dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT kotsukamasaya dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT miyaratakayuki dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage AT koderayasuhiro dualcenterrandomizedclinicaltrialexploringtheoptimaldurationofantimicrobialprophylaxisinpatientsundergoingpancreaticoduodenectomyfollowingbiliarydrainage |